drugset
drugset / Trial / NCT02956525

Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions

NCT02956525 ↗

Phase 1 Completed 52 enrolled Apsen Farmaceutica S.A.
RandomizedParallel-groupOpen-labelOther

Summary

Phase I Study to Evaluate the Safety of Dexibuprofen 200mg (Apsen Pharmaceuticals A / S.) After a Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.

Timeline

Start
2018-04-01
Primary completion
2018-07-01
Completion
2018-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexibuprofen Small molecule 200 mg Oral

Indications

No indication recorded.